Back to Search
Start Over
TRIM31 enhances chemoresistance in glioblastoma through activation of the PI3K/Akt signaling pathway
- Source :
- Experimental and Therapeutic Medicine
- Publication Year :
- 2019
-
Abstract
- Temozolomide (TMZ) resistance is a complication of treatment of glioma, and new strategies are urgently required to overcome chemoresistance in glioma cells. In the present study, it was demonstrated that tripartite motif-containing 31 (TRIM31) was abnormally upregulated in glioma tissues and cell lines compared with normal samples. Furthermore, the role of TRIM31 was assessed by overexpressing and knocking down its expression. Overexpression of TRIM31 increased cell viability, increased TMZ IC50 values and inhibited apoptosis in A172 and U251 cells; whereas overexpression of TRIM31 decreased the expression of the apoptosis-associated protein p53. Knockdown of TRIM31 increased apoptosis in cells treated with TMZ. Additionally, the mechanisms by which TRIM31 affected glioma cells treated with TMZ were determined. Overexpression of TRIM31 increased phosphorylation of AKT and inhibiting the PI3K/AKT signaling pathway abolished the increase in cell viability and decreased phospho-Akt protein expression in TRIM31 overexpressing A172 cells treated with TMZ. Together, the findings suggest that TRIM31 may be a potentially novel target for glioma chemotherapy.
- Subjects :
- 0301 basic medicine
Cancer Research
03 medical and health sciences
0302 clinical medicine
Immunology and Microbiology (miscellaneous)
Glioma
medicine
Viability assay
Protein kinase B
PI3K/AKT/mTOR pathway
PI3K/Akt
Temozolomide
Akt/PKB signaling pathway
Chemistry
glioblastoma
apoptosis
chemoresistance
Articles
General Medicine
tripartite motif-containing 31
Cell cycle
medicine.disease
030104 developmental biology
Apoptosis
030220 oncology & carcinogenesis
Cancer research
medicine.drug
Subjects
Details
- ISSN :
- 17920981
- Volume :
- 20
- Issue :
- 2
- Database :
- OpenAIRE
- Journal :
- Experimental and therapeutic medicine
- Accession number :
- edsair.doi.dedup.....48afec7c07626d0635e08288f830b32f